"$20 Million or more ?" Nope, less than $3
But is was a NICE STORY.
The hype about the potential winnings from TAUG's law suit vastly exceeded the results.
How about the excitement about RollLeaf. Press releases about it including progress reports, pictures of the bottle and close ups of the label. Lot's of spirited debate about how promising it was, or wasn't. NICE STORY, NO RESULTS.
What about the HERMAN lip balm and the many posts about it's immanent sales deployment to a HUGE number of retailers. NICE STORY, NO RESULTS.
How about TAUG's Pfizer connections? Frank 0. is a Senior Pfizer Finance "executive" with a HUGE budget and many potential M&A contacts. After over a year of hype - NICE STORY, NO RESULTS.
Or as rawman puts it - Seth throws lots of stuff against the wall, but none of it sticks. Note that his statement isn't just about 2017. It's about all of Seth's years as an executive. Not a single business success!
But what about the future. A big part of the strategy appears to be to try and jump on the block-chain (e.g. Bitcoin) bubble. Oh, and there's also Seth's frequently hyped Rolodex. That hasn't produced any shareholder benefit before. But this time will be different. Seth has many companies eager to invest in TAUG for more than 10 times TAUG's market value. When I've asked why, a company would pay much more for TAUG, than they could buy it for in the open market, the only answers I got were attempts to change the subject.
A M&A deal that increases the value of TAUG shareholder's investment by 10x is even less likely than the "$20 Million or more - you Betcha" hype. NICE STORY, NO RESULTS? Actually, no. It's not a really NICE STORY, it's a lame one.
Who would pay a premium for TAUG in its current state? The TAUG M&A possibility is just another STORY.
